Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-05
2011-04-05
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S277400
Reexamination Certificate
active
07919512
ABSTRACT:
Compounds of general formula (II)whereinW is chloro or fluoro;R1is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2whereineach R2is independently hydrogen, —C1-C6alkyl, —C3-C8cycloalkyl, aryl or heteroaryl;each R3is independently, —C1-C6alkyl, —C3-C8cycloalkyl, aryl or heteroaryl;p and q are each independently an integer from 1 to 3; andR4is hydrogen, C1-C6alkyl, C1-C6alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2or CH((CH2)mO(C═O)R6)2;m is 1 or 2;n is 1-4;X is OR5or N(R5)2;R5is hydrogen or methyl; andR6is C1-C18alkyl;and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
REFERENCES:
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4273782 (1981-06-01), Cross et al.
patent: 4363912 (1982-12-01), Cross et al.
patent: 4478842 (1984-10-01), Renfroe
patent: 4774240 (1988-09-01), Böshagen et al.
patent: 4859692 (1989-08-01), Bernstein et al.
patent: 5214059 (1993-05-01), Tegeler et al.
patent: 5410061 (1995-04-01), Gilmore et al.
patent: 5496844 (1996-03-01), Inai et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5578634 (1996-11-01), Bach et al.
patent: 5641800 (1997-06-01), Bach et al.
patent: 5744488 (1998-04-01), Cross et al.
patent: 6500853 (2002-12-01), Seehra et al.
patent: 6521659 (2003-02-01), Sredy et al.
patent: 6555568 (2003-04-01), Sredy et al.
patent: 6602890 (2003-08-01), Höfgen et al.
patent: 6730794 (2004-05-01), Jones et al.
patent: 6797708 (2004-09-01), McKew et al.
patent: 6828344 (2004-12-01), Seehra et al.
patent: 6916841 (2005-07-01), Seehra et al.
patent: 6995263 (2006-02-01), Ackermann et al.
patent: 7166607 (2007-01-01), Bonnert et al.
patent: 7321001 (2008-01-01), Fu et al.
patent: 7348351 (2008-03-01), Jennings et al.
patent: 7405215 (2008-07-01), Bennani et al.
patent: 7534897 (2009-05-01), Tanimoto et al.
patent: 7582672 (2009-09-01), Middlemiss et al.
patent: 7601749 (2009-10-01), Bennani et al.
patent: 2001/0044437 (2001-11-01), Robinson et al.
patent: 2005/0222201 (2005-10-01), Birkinshaw et al.
patent: 2006/0111426 (2006-05-01), Bonnert et al.
patent: 2006/0264444 (2006-11-01), Bonnert et al.
patent: 2007/0232681 (2007-10-01), Middlemiss et al.
patent: 2008/0027092 (2008-01-01), Bonnert et al.
patent: 2008/0255100 (2008-10-01), Bennani et al.
patent: 2008/0306109 (2008-12-01), Hynd et al.
patent: 2009/0030014 (2009-01-01), Kugimiya et al.
patent: 2009/0163518 (2009-06-01), Bonnert et al.
patent: 2009/0170897 (2009-07-01), Corradini et al.
patent: 2009/0186923 (2009-07-01), Armer et al.
patent: 2009/0192195 (2009-07-01), Armer et al.
patent: 2009/0286825 (2009-11-01), Wang
patent: 2010/0004240 (2010-01-01), Giblin et al.
patent: 2010/0016371 (2010-01-01), Giblin et al.
patent: 2010/0016389 (2010-01-01), Bennani et al.
patent: 2010/0022613 (2010-01-01), Armer et al.
patent: 2010/0035956 (2010-02-01), Armer et al.
patent: 2010/0041699 (2010-02-01), Boyd et al.
patent: 2010/0056544 (2010-03-01), Lovell
patent: 2010/0063103 (2010-03-01), Armer et al.
patent: 0 984 012 (2000-03-01), None
patent: 1 356 834 (1974-07-01), None
patent: 2 422 829 (2006-08-01), None
patent: 2 422 830 (2006-08-01), None
patent: 2 422 831 (2006-08-01), None
patent: 2001-247570 (2001-09-01), None
patent: WO 2003/066047 (2003-08-01), None
patent: WO 2005/121141 (2005-12-01), None
patent: WO 2006/092579 (2006-09-01), None
patent: WO 2006/095183 (2006-09-01), None
patent: WO 2007/010964 (2007-01-01), None
patent: WO 2007/019675 (2007-02-01), None
patent: WO 2007/107772 (2007-09-01), None
patent: WO 2009/037503 (2009-03-01), None
patent: WO 2009/063202 (2009-05-01), None
patent: WO 2009/063215 (2009-05-01), None
patent: WO 2009/077728 (2009-06-01), None
patent: WO 2009/090399 (2009-07-01), None
patent: WO 2009/093026 (2009-07-01), None
patent: WO 2010/008864 (2010-01-01), None
Armer, R.E., et al., “Indole-3-acetic acid antagonists of the prostaglandin D2receptor CRTH2,”J. Med. Chem. 48:6174-6177, American Chemical Society (2005).
Cross, P.E., et al., “Selective Thromboxane Synthetase Inhibitors. 2. 3-(1H-Imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic Acid and Analogues,”J. Med. Chem. 29:342-345, American Chemical Society (1986).
Abstract of Gillard, J.W., et al., “Indole 2-Propanoic Acids: The Medicinal Chemistry of L-665,240 a Potent, Non-Prostanoid Thromboxane Antagonist,” Abstracts of Papers, ORGN-327, 195th ACS National Meeting, Toronto, Ontario, Canada, American Chemical Society (1988).
Johnson, M.G., et al., “Indole-phenylacetic acid inhibitors of CRTH2,” Abstracts of Papers, MEDI-064, 235th ACS National Meeting, New Orleans, LA, American Chemical Society (2008).
Kumar, S., et al., “Novel indium-mediated ternary reactions between indole-3-carboxaldehydes-allyl bromide-enamines: facile synthesis of bisindolyl- and indolyl-heterocyclic alkanes,”Tetrahedron Letters 44:2101-2104, Elsevier Science Ltd. (2003).
Matassa, V.G., et al., “Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles,”J. Med. Chem. 33:1781-1790, American Chemical Society (1990).
Mathieson, J.M., et al., “Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2,”Mol. Pharmacol. 68:693-402, The American Society for Pharmacology and Experimental Therapeutics (2005).
Royer, J.F., et al., “A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils,”Eur. J. Clin. Invest. 38:663-671, Wiley-Blackwell (2008).
Embase, Accession No. 2005230213, Abstract of Werz, O. and Dieter, S., “Pharmacological intervention with 5-lipoxygenase: New insights and novel compounds,”Expert Opin. Ther. Pat. 15:505-519, Informa Healthcare (2005).
Patent Abstracts of Japan, English language abstract of JP 2001-247570 (listed as document FP3 on accompanying form PTO/SB/08A).
Armer Richard Edward
Pettipher Eric Roy
Schröer Frank
Vile Julia
Whittaker Mark
Fetterolf Brandon J
Oxagen Limited
Ricci Craig
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Compounds having CRTH2 antagonist activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having CRTH2 antagonist activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having CRTH2 antagonist activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648006